Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of CIK Cells in Autologous Hematopoietic Stem Cell Transplant Recipients
NCT07692607Completed
- Sponsor
- LucasBio
- Start
- Mar 2022
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial of unmodified CIK in lymphoma, sponsored by LucasBio. Primary endpoints: Adverse Event Assessment at 24 months and Progression-Free Survival Ratio at 24 months. Started Mar 2022; status: completed.
02
Drugs
unmodified CIK
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT07692607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692607.